NEW YORK, Feb 15 – George Soros’ company Soros Fund Management reduced its holding in CuraGen but maintained its stake in CuraGen’s privately held subsidiary, 454, a CuraGen spokesman said Thursday.

“Soros unloaded literally all of his biotech holdings, and we were one that he maintained his position in,” a CuraGen spokesman said. “We saw this as a vote of confidence.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.